Effects of PACE Technique in Patients With Aphasia

April 2, 2026 updated by: Riphah International University

Aphasia, a communication disorder often resulting from him brain injury such as stroke, impacts an individual's ability to understand or produce language. It can manifest in various forms, such as difficulties with speaking, writing, reading, and comprehension, which severely impair daily functioning and quality of life. For adults with aphasia, regaining communication skills is often a critical aspect of rehabilitation, demanding a combination of therapeutic strategies.

The Promoting Aphasics' Communicative Effectiveness (PACE) technique is a widely recognized approach to improve communication in individuals with aphasia. Developed in the late 20th century, the PACE technique focuses on naturalistic communication, encouraging patients to utilize any available communicative means verbal or non-verbal to convey messages effectively. By simulating real-world conversational scenarios in therapy, PACE aims to enhance both expressive and receptive communication skills, thereby facilitating better interaction in social contexts. This approach is especially beneficial for individuals with severe expressive language impairments, as it emphasizes the overall success of communication rather than linguistic accuracy.

A descriptive experimental research design was followed in the present study to explore the effect of PACE technique in adults with Aphasia. The study will be conducted at DHQ Faisalabad. The Duration of study is relied on 16 sessions. Three sessions will be conducted per week and the duration of a session is about forty minutes. Sample size (N=16) (Control group =8, Experimental group=8). Patients who were identified with mile to moderate level of Aphasia are age of 45 to 65 years old. Group A will be an experimental group (who will receive both Conventional and Promoting Aphasic Communicative Effectiveness technique). Group B will be a controlled group (who will receive just Conventional Therapy). A randomized Clinical trial will employ to collect data from participants approach at DHQ Faisalabad.

Study Overview

Status

Status

Indicates the current recruitment status or the expanded access status.
Completed

Conditions

Conditions

The disease, disorder, syndrome, illness, or injury that is being studied. On ClinicalTrials.gov, conditions may also include other health-related issues, such as lifespan, quality of life, and health risks.

Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.

Detailed Description

This approach is especially beneficial for individuals with severe expressive language impairments, as it emphasizes the overall success of communication rather than linguistic accuracy. A descriptive experimental research design was followed in the present study to explore the effect of PACE technique in adults with Aphasia. The study will be conducted at DHQ Faisalabad. Sample size (N=16) (Control group =8, Experimental group=8). Patients who were identified with mild to moderate level of Aphasia are age of 45 to 65 years old. Group A will be an experimental group (who will receive both Conventional and Promoting Aphasic Communicative Effectiveness technique). Group B will be a controlled group (who will receive just Conventional Therapy). A randomized Clinical trial will employ to collect data from participants approach at DHQ Faisalabad.

Study Type

Study Type

Describes the nature of a clinical study. Study types include interventional studies (also called clinical trials), observational studies (including patient registries), and expanded access.
Interventional

Enrollment (Actual)

Enrollment

The number of participants in a clinical study. The "anticipated" enrollment is the target number of participants that the researchers need for the study.
16

Phase

Phase

The stage of a clinical trial studying a drug or biological product, based on definitions developed by the U.S. Food and Drug Administration (FDA). The phase is based on the study's objective, the number of participants, and other characteristics. There are five phases: Early Phase 1 (formerly listed as Phase 0), Phase 1, Phase 2, Phase 3, and Phase 4. Not Applicable is used to describe trials without FDA-defined phases, including trials of devices or behavioral interventions.
  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Pakistan
    • Punjab Province
      • Faisalābad, Punjab Province, Pakistan, 38000
        • District Headquarter

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Eligibility Criteria

The key requirements that people who want to participate in a clinical study must meet or the characteristics they must have. Eligibility criteria consist of both inclusion criteria (which are required for a person to participate in the study) and exclusion criteria (which prevent a person from participating). Types of eligibility criteria include whether a study accepts healthy volunteers, has age or age group requirements, or is limited by sex.

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

Yes

Description

Inclusion Criteria:

  • Age: Patients from age 45-65 years will be included in the study

    1. Both gender male and female will be included in the study.
    2. Diagnosed Adults with aphasia will be included in the study.
    3. Severity level: Mild to moderate will be included in the study
    4. Only non-fluent type of Aphasia will be included in the study

Exclusion Criteria:

  • Adult with any co-morbid condition will be excluded from study.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Single

Arms and Interventions

Participant Group / Arm

Participant Group / Arm

A group or subgroup of participants in a clinical trial that receives a specific intervention/treatment, or no intervention, according to the trial's protocol.
Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.
Experimental: pace therapy

In a clinical trial or intervention study, the number of arms refers to the different groups that receive specific types of treatment or intervention. Each "arm" represents a distinct study condition. Here are common types of arms in PACE (Promoting Aphasics' Communicative Effectiveness) intervention studies:

1. Experimental Arm (PACE Intervention) Participants receive PACE therapy, which encourages multimodal communication (speech, gestures, writing, drawing, etc.) in a conversational setting.

The focus is on functional communication rather than perfect speech production.
Behavioral: experimental
Promoting Aphasics' Communicative Effectiveness (PACE) is a functional approach to aphasia intervention that emphasizes natural, interactive communication between the clinician and the individual with aphasia. Unlike traditional therapy, which often focuses on accuracy, PACE encourages any form of communication-verbal or non-verbal-such as gestures, drawing, writing, or using augmentative devices. The therapy is conducted in a conversational setting, where both participants exchange new information, ensuring the person with aphasia takes an active role in communication. By reducing pressure and promoting alternative communication strategies, PACE enhances confidence, encourages spontaneous language use, and helps individuals regain functional communication skills in real-life situations
Active Comparator: control group conventional therapy
2. Control Arm (Standard Therapy or No Treatment) Participants receive either traditional speech therapy (e.g., structured drills, naming tasks) or no treatment for comparison.
Other: control group conventional therapy
Control Arm (Standard Therapy or No Treatment) Participants receive either traditional speech therapy (e.g., structured drills, naming tasks) or no treatment for comparison.

What is the study measuring?

Primary Outcome Measures

Primary Outcome Measures

In a clinical study's protocol, the planned outcome measure that is the most important for evaluating the effect of an intervention/treatment. Most clinical studies have one primary outcome measure, but some have more than one.
Outcome Measure
Measure Description
Time Frame
Mississippi Aphasia Screening Test
Time Frame: 6 to 8 weeks
The Mississippi Aphasia Screening Test (MAST) is a brief and efficient tool designed to assess language abilities in individuals with aphasia, particularly those who have experienced a stroke or brain injury. It is a standardized screening test that evaluates various aspects of language function, including expressive and receptive abilities. The MAST consists of simple tasks such as naming, repetition, following commands, and verbal fluency, allowing clinicians to quickly identify language impairments. It is widely used due to its reliability, ease of administration, and effectiveness in detecting aphasia in both clinical and research setting
6 to 8 weeks

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Sponsor

The organization or person who initiates the study and who has authority and control over the study.
Riphah International University

Investigators

Investigators

A researcher involved in a clinical study. Related terms include site principal investigator, site sub-investigator, study chair, study director, and study principal investigator.
  • Principal Investigator: Mehwish Ikhlaque, MS, Riphah International University, Lahore

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

Study Start

The actual date on which the first participant was enrolled in a clinical study. The "anticipated" study start date is the date that the researchers think will be the study start date.
March 18, 2025

Primary Completion (Actual)

Primary Completion

The date on which the last participant in a clinical study was examined or received an intervention to collect final data for the primary outcome measure. Whether the clinical study ended according to the protocol or was terminated does not affect this date. For clinical studies with more than one primary outcome measure with different completion dates, this term refers to the date on which data collection is completed for all the primary outcome measures. The "anticipated" primary completion date is the date that the researchers think will be the primary completion date for the study.
June 20, 2025

Study Completion (Actual)

Study Completion

The date on which the last participant in a clinical study was examined or received an intervention/treatment to collect final data for the primary outcome measures, secondary outcome measures, and adverse events (that is, the last participant's last visit). The "anticipated" study completion date is the date that the researchers think will be the study completion date.
June 29, 2025

Study Registration Dates

First Submitted

First Submitted

The date on which the study sponsor or investigator first submitted a study record to ClinicalTrials.gov. There is typically a delay of a few days between the first submitted date and the record's availability on ClinicalTrials.gov (the first posted date).
April 2, 2026

First Submitted That Met QC Criteria

First Submitted That Met QC Criteria

The date on which the study sponsor or investigator first submits a study record that is consistent with National Library of Medicine (NLM) quality control (QC) review criteria. The sponsor or investigator may need to revise and submit a study record one or more times before NLM's QC review criteria are met. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
April 2, 2026

First Posted (Actual)

First Posted

The date on which the study record was first available on ClinicalTrials.gov after National Library of Medicine (NLM) quality control (QC) review has concluded. There is typically a delay of a few days between the date the study sponsor or investigator submitted the study record and the first posted date.
April 9, 2026

Study Record Updates

Last Update Posted (Actual)

Last Update Posted

The most recent date on which changes to a study record were made available on ClinicalTrials.gov. There may be a delay between when the changes were submitted to ClinicalTrials.gov by the study's sponsor or investigator (the last update submitted date) and the last update posted date.
April 9, 2026

Last Update Submitted That Met QC Criteria

Last Update Submitted That Met QC Criteria

The most recent date on which the study sponsor or investigator submitted changes to a study record that are consistent with National Library of Medicine (NLM) quality control (QC) review criteria. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
April 2, 2026

Last Verified

Last Verified

The most recent date on which the study sponsor or investigator confirmed the information about a clinical study on ClinicalTrials.gov as accurate and current. If a study with a recruitment status of recruiting; not yet recruiting; or active, not recruiting has not been confirmed within the past 2 years, the study's recruitment status is shown as unknown.
April 1, 2026

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

Other Study ID Numbers

Identifiers or ID numbers other than the NCT number that are assigned to a clinical study by the study's sponsor, funders, or others. These numbers may include unique identifiers from other trial registries and National Institutes of Health grant numbers.
  • rec/rcr&ahs/24/0682

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Aphasia, Broca

Clinical Trials on experimental

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Cookie Settings

We use cookies to ensure that we give you the best experience on our website. For more details carefully read our Privacy and Cookies Policy. ...>>>You can change your preferences or withdraw your consent at any time by deleting the cookies from your website or computer as described in the policy. Please accept it and choose your preferences by ticking the corresponding boxes in the "Manage Settings" section below. Please carefully read our Terms of Service before you proceed with using any part of this website.
«Manage Settings